FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:29:138 | Cetylated fatty acids and fibromyalgia: efficacy and tolerability in a prospective study Anna Capogna1, Marco Bardelli1, Luca Cantarini1, Bruno Frediani1 | 1UOC Reumatologia, Dipartimento di Scienze mediche, chirurgiche e neuroscienze, Università degli Studi di Siena, Italy
71 -
PO:02:016 | Real-world evidence of upadacitinib over two years in Italian patients with axial spondyloarthritis Mariagrazia Lorenzin1, Giacomo Cozzi1, Stefano Gentileschi2, Michele Maria Luchetti Gentiloni3, Antonio Carletto4, Maria Sole Chimenti5, Maria Manara6, Luca Quartuccio7, Rosario Foti8, Salvatore D'Angelo9, Ariela Hoxha10, Carlo Selmi11, Bernd Raffeiner12, Alessandro Giollo1, Alberto Cauli13, Carlo Salvarani14, Fabiola Atzeni15, Roberta Ramonda1, Sir Study Group Spa E Psa Antonio Spadaro16. | 1Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy; 2Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 3Clinica Medica, Ospedali Riuniti Ancona University Hospital, Ancona; Department of Clinical and Molecular Sciences, Ancona, Italy; 4Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Italy; 5Rheumatology, allergology and clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy; 6Humanitas San Pio X, Milano, Italy; 7University of Udine, Academic Hospital Santa Maria della Misericordia, Udine, Italy; 8Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania, Italy; 9Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; 10Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine-DIMED, University of Padua, Padova, Italy; 11Department of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 12Department of Rheumatology, Teaching Hospital of the Paracelsius Medical Hospital of Bolzano ASAA-SABES, Bolzano, Italy; 13Rheumatology Unit, Department of Medical Sciences, AOU and University of Cagliari, Monserrato, Cagliari, Italy; 14Department of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena and Reggio Emilia, Reggio Emilia, Italy; 15Rheumatology Unit, University of Messina, Messina, Italy; 16Società Italiana di Reumatologia, Milano, Italy.
73 -
CO:11:5 | Laboratory preliminary results from an open label, prospective, phase ii descriptive pilot trial of belimumab therapy for refractory and/or non criteria manifestations of antiphospholipid syndrome Alice Barinotti1, Massimo Radin1, Irene Cecchi1, Beatrice Ala1, Chiara Raymondi1, Elena Rubini1, Silvia G. Foddai1, Lois Ira Maniulit Capulong1, Alessio Conti1, Alessandro Morotti1, Dario Roccatello1, Roberta Fenoglio1, Savino Sciascia1. | 1Università di Torino, Italy.
68 -
PO:05:069 | Risankizumab efficacy in peripheral and axial involvement: monocentric experience Roberta Foti1, Ylenia Dal Bosco1, Giorgio Amato1, Elisa Visalli1, Francesco De Lucia1, Gabriella Paolí1, Rosario Foti1. | 1UOSD Reumatologia AOU Policlinico G. Rodolico-S. Marco, Catania, Italy.
65 -
PO:28:126 | Effectiveness of the new AMEL system in the treatment of simple painful shoulder syndrome Antonietta Albanese1, Emilio Battisti1, Federico Filippi2 | 1Dipartimento SFTA, Università di Siena, Siena; 2Sanimed, Fisiomed, Vicenza, Italy
101 -
PO:03:036 | Psoriatic arthritis: does pre-existing treatment with cs/bDMARDs for psoriasis influence the characteristics and outcomes of joint disease? Ilenia Marchesini1, Alberto Floris1, Cristina Mugheddu2, Laura Li Volsi1, Maria Teresa Paladino1, Roberta Origa1, Jessica Sorgia1, Mattia Congia1, Elisabetta Chessa1, Matteo Piga1, Caterina Ferreli2, Laura Atzori2, Alberto Cauli1 | 1Unità di Reumatologia, AOU e Università di Cagliari-Monserrato; 2Unità di Dermatologia, AOU e Università di Cagliari, Italy
84 -
PO:01:010 | Survival of second-line treatment with TNF inhibitors vs. IL-23 inhibitors after failure of a first TNF inhibitor: a real-life observational study from the Italian multicenter BIRRA cohort in patients with psoriatic arthritis Francesca Ometto1, Olga Addimanda2, Bernd Raffeiner3, Alberto Lo Gullo4, Elisa Visalli5, Eleonora Celletti6, Antonella Farina7, Maddalena Larosa8, Romina Andracco9, Marino Paroli10, Patrizia Del Medico11, Aldo Biagio Molica Collella12, Federica Lumetti13, Gilda Sandri14, Marta Priora15, Aurora Ianiello16, Elena Bravi17, Alessandra Bezzi18, Palma Scolieri19, Simone Parisi20, Viviana Ravagnani20, Rosetta Vitetta20, Luca Idolazzi20, Riccardo Bixio20, Gianluca Santoboni20, Francesco Girelli20, Alarico Ariani20 | 1Azienda ULSS 6 Euganea, Padova; 2UOC Interaziendale di Medicina Interna ad Indirizzo Reumatologico, AUSL BO - IRCCS AOU Bologna; 3Unità di Reumatologia, Teaching Hospital of the Paracelsius Medical University, Central Hospital of Bolzano (ASAA-SABES) Bolzano; 4UOD Reumatologia, ARNAS Garibaldi Catania; 5UO Reumatologia, Policlinico San Marco Hospital Catania; 6UOS Reumatologia, Ospedale SS. Annunziata, Università G. d'Annunzio, Chieti; 7UOC Medicina Interna- Ambulatorio Reumatologico, Ospedale A. Murri, Fermo; 8S.C. Reumatologia, Dipartimento Specialità Mediche, Ospedale La Colletta-Azienda Sanitaria Locale 3 Genova; 9Ambulatorio Reumatologia, Ospedale di Imperia; 10Sapienza Università Polo Pontino, Latina; 11Ambulatorio di Reumatologia, UO Medicina Interna, Civitanova Marche Hospital, Civitanova (MC); 12UOSD di Reumatologia, Azienda Ospedaliera Papardo Messina; 13Unità di Reumatologia, Azienda USL di Modena e Ospedale Universitario Policlinico di Modena; 14Unità di Reumatologia, Università di Modena e Reggio Emilia Modena; 15Ambulatorio e Day Hospital di Reumatologia, ASL CN1, Mondovì (CN); 16Poliambulatorio specialistico di reumatologia e Day Hospital multidisciplinare di area Medica, ASL Novara; 17UOSD Reumatologia, Ospedale G. Da Saliceto, Piacenza; 18UO Medicina Interna e Reumatologia, SS Reumatologia, ASL Romagna, Rimini; 19UOC Medicina Interna e Reumatologia, Ospedale Nuovo Regina Margherita, Roma; 20Gruppo BIRRA Italy
92 -
PO:36:243 | Drug survival, discontinuation reasons and disease activity in patients with Behçet's disease treated with infliximab - a real-life study Antonello Sulis1, Federica Di Cianni1, Maria Laura Manca2, Rosaria Talarico1, Marta Mosca1. | 1Rheumatology Unit of Pisa, University of Pisa, Pisa, Italy, Pisa, Italy; 2Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Italy, Pisa, Italy.
65 -
